Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180070 | 0.78 | MEN1 (0.31) | KMT2AMEN1LMNA | |
| SCHEMBL1031414 | 0.78 | GRIN1 (0.30) | GRIN1GRIN2B | |
| SCHEMBL1032886 | 0.77 | F2RL3 (0.31) | MAPT | |
| SCHEMBL1035285 | 0.74 | KDM4E (0.32) | RXRAGRIN1GRIN2BMAPT | |
| SCHEMBL2178912 | 0.74 | SCN5A (0.31) | — | |
| SCHEMBL2175980 | 0.74 | — | — | |
| SCHEMBL895932 | 0.74 | — | — | |
| SCHEMBL1024313 | 0.73 | TRPA1 (0.33) | — | |
| SCHEMBL2176126 | 0.73 | ADORA2A (0.30) | — | |
| SCHEMBL2178393 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353174-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL]AMIDES USEFUL AS BACE INHIBITORS | Pfizer Inc (US) | 2018-08-01 | — | — | EP | claimed |
| EP-3353182-A1 | TETRAHYDROPYRANO[3,4-D][1,3]OXAZIN DERIVATIVES AND THEIR USE AS BACE INHIBITORS | Pfizer Inc (US) | 2018-08-01 | — | — | EP | claimed |
| US-9771379-B2 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides | PFIZER INC. (US) | 2017-09-26 | — | — | US | claimed |
| US-9611264-B1 | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides | PFIZER INC. (US) | 2017-04-04 | — | — | US | claimed |
| US-20170088547-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | US | claimed |
| WO-2017051294-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES USEFUL AS BACE INHIBITORS | PFIZER INC. (US) | 2017-03-30 | — | — | WO | claimed |
| WO-2017051303-A1 | TETRAHYDROPYRANO[3,4-D][1,3]OXAZIN DERIVATIVES AND THEIR USE AS BACE INHIBITORS | PFIZER INC. (US) | 2017-03-30 | — | — | WO | claimed |
| US-20170088556-A1 | N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | US | claimed |
| US-8299262-B2 | Pyridylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-10-30 | — | — | US | claimed |
| JP-2011506281-A | — | — | 2011-03-03 | — | — | JP | claimed |
| EP-2262794-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE AS FUNGICIDE | BASF SE (DE) | 2010-12-22 | — | — | EP | claimed |
| US-20100317516-A1 | Sulfonamide Compounds And Their Use As Fungicide | BASF SE (DE) | 2010-12-16 | — | — | US | claimed |
| US-20100249077-A1 | Pyridylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-09-30 | — | — | US | claimed |
| EP-2231605-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2010-09-29 | — | — | EP | claimed |
| WO-2009103650-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE AS FUNGICIDE | BASF SE (DE) | 2009-08-27 | — | — | WO | claimed |
| WO-2009071449-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | claimed |
| WO-2009071448-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | claimed |
| US-10253042-B2 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides | PFIZER INC. (US) | 2019-04-09 | — | — | US | disclosed |
| WO-2009112533-A1 | SUBSTITUTED TRIAZINYLMETHYL SULFONAMIDES | BASF SE (DE) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009103650-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE AS FUNGICIDE | BASF SE (DE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088547-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R, TH | HRH4 138/4885KMT2A 2622/4885RXRA 1570/4885 |
| US-20100317516-A1 | Sulfonamide Compounds And Their Use As Fungicide | STS, ARSA, CYP4X1 | HRH4 200/4885KMT2A 632/4885RXRA 142/4885 |
| US-20170088556-A1 | N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, NPY4R | HRH4 42/4885KMT2A 2749/4885RXRA 677/4885 |
| US-20100249077-A1 | Pyridylmethyl-Sulfonamide Compounds | CBR3, CBR1, CBS | HRH4 94/4885KMT2A 2656/4885RXRA 3731/4885 |
| US-10253042-B2 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, NPY4R | HRH4 42/4885KMT2A 2749/4885RXRA 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.